Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Accenture
Teva
Mallinckrodt
Boehringer Ingelheim
US Department of Justice

Generated: August 24, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,770,406

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,770,406 protect, and when does it expire?

Patent 9,770,406 protects VEREGEN and is included in one NDA.

This patent has thirty-one patent family members in twenty countries.

Summary for Patent: 9,770,406
Title:Medicament for the treatment of viral skin and tumour diseases
Abstract: The invention relates to a medicament containing a compound of general formula (I), where R.sub.1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C.sub.11-C.sub.21 alkyl, alkylene or alkinyl group, preferably a C.sub.11-C.sub.15 alkyl, alkylene or alkinyl group, particularly a C.sub.11-C.sub.13 alkyl, alkylene or alkinyl group, most preferably a C.sub.13 alkyl group, R.sub.2=independently, a straight or branched C.sub.1-C.sub.8 alkyl, alkylene or alkinyl group, preferably a C.sub.1-C.sub.6 alkyl, alkylene or alkinyl group, in particular a C.sub.2-C.sub.4 alkyl, alkylene or alkinyl group, most preferably a C.sub.3 alkyl group, a --[CH.sub.2--(CH.sub.2)m-O].sub.nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a --CH.sub.2--[CH--(OH)].sub.p[CH.sub.2--R.sub.3]- group, where R.sub.3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.
Inventor(s): Chang; Yunik (Sonoma, CA), Lathrop; Robert (Fort Collins, CO), Bohm; Erwin (Ladenburg, DE), Gander-Meisterernst; Irene (Stockdorf, DE), Greger; Regina (Iffeldorf, DE), Holldack; Johanna (Aarhus C, DK), Moebius; Ulrich (Gauting-Unterbrunn, DE)
Assignee: Medigene AG (Planegg/Martinsried, DE)
Application Number:12/887,250
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 9,770,406

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Fougera Pharms Inc VEREGEN sinecatechins OINTMENT;TOPICAL 021902-001 Oct 31, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF GENITAL WARTS ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,770,406

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10156794Nov 19, 2001

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Fish and Richardson
Cipla
Farmers Insurance
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.